Page 1 | Search Results | Hematology, ASH Education Program

1-20 of 84

Sort by

Sort Order Select

Journal Articles

Opportunities for immunotherapy in childhood acute myeloid leukemia

Adam J. Lamble, Sarah K. Tasian

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 218–225.

https://doi.org/10.1182/hematology.2019000357

Published: 2019

Journal Articles

Minimal residual disease and stem cell transplantation outcomes

Jacqueline Cloos, Gert J. Ossenkoppele, Richard Dillon

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 617–625.

https://doi.org/10.1182/hematology.2019000006

Published: 2019

Journal Articles

Single-agent and combination biologics in acute myeloid leukemia

Guillaume Richard-Carpentier, Courtney D. DiNardo

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 548–556.

https://doi.org/10.1182/hematology.2019000059

Published: 2019

Journal Articles

In MDS, is higher risk higher reward?

Guillermo F. Sanz

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 381–390.

https://doi.org/10.1182/hematology.2019000042

Published: 2019

Journal Articles

MRD evaluation of AML in clinical practice: are we there yet?

Sylvie D. Freeman, Christopher S. Hourigan

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 557–569.

https://doi.org/10.1182/hematology.2019000060

Published: 2019

Journal Articles

Evidence-Based Minireview: Longitudinal geriatric assessment in quality care for older patients with hematologic malignancies

Richard J. Lin, Heidi D. Klepin

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 59–62.

https://doi.org/10.1182/hematology.2019000076

Published: 2019

Journal Articles

Genetic predisposition to MDS: diagnosis and management

Elissa Furutani, Akiko Shimamura

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 110–119.

https://doi.org/10.1182/hematology.2019000021

Published: 2019

Journal Articles

Moving immunotherapy into the front line in ALL

Amanda Winters, Lia Gore

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 209–217.

https://doi.org/10.1182/hematology.2019000017

Published: 2019

Journal Articles

Monitoring and treatment of MDS in genetically susceptible persons

Stella M. Davies

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 105–109.

https://doi.org/10.1182/hematology.2019000020

Published: 2019

Journal Articles

The MDS genomics-prognosis symbiosis

Aziz Nazha

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 270–276.

https://doi.org/10.1182/asheducation-2018.1.270

Published: 2018

Journal Articles

When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter

Gregory W. Roloff, Elizabeth A. Griffiths

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 35–44.

https://doi.org/10.1182/asheducation-2018.1.35

Published: 2018

Journal Articles

Cytotoxic therapy in acute myeloid leukemia: not quite dead yet

Laura C. Michaelis

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 51–62.

https://doi.org/10.1182/asheducation-2018.1.51

Published: 2018

Journal Articles

New drugs for acute myeloid leukemia inspired by genomics and when to use them

Daniel A. Pollyea

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 45–50.

https://doi.org/10.1182/asheducation-2018.1.45

Published: 2018

Journal Articles

Old and new tools in the clinical diagnosis of inherited bone marrow failure syndromes

Allison H. West, Jane E. Churpek

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 79–87.

https://doi.org/10.1182/asheducation-2017.1.79

Published: 2017

Journal Articles

Inherited bone marrow failure syndromes: considerations pre- and posttransplant

Blanche P. Alter

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 88–95.

https://doi.org/10.1182/asheducation-2017.1.88

Published: 2017

Journal Articles

Classification and risk assessment in AML: integrating cytogenetics and molecular profiling

Matahi Moarii, Elli Papaemmanuil

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 37–44.

https://doi.org/10.1182/asheducation-2017.1.37

Published: 2017

Journal Articles

The role of targeted therapy in the management of patients with AML

Alexander E. Perl

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 54–65.

https://doi.org/10.1182/asheducation-2017.1.54

Published: 2017

Journal Articles

Fitness in the elderly: how to make decisions regarding acute myeloid leukemia induction

Arati V. Rao

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 339–347.

https://doi.org/10.1182/asheducation-2016.1.339

Published: 2016

Journal Articles

MRD in AML: does it already guide therapy decision-making?

Gert Ossenkoppele, Gerrit Jan Schuurhuis

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 356–365.

https://doi.org/10.1182/asheducation-2016.1.356

Published: 2016

Journal Articles

Acute myeloid leukemia in children and adolescents: identification of new molecular targets brings promise of new therapies

E. Anders Kolb, Soheil Meshinchi

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 507–513.

https://doi.org/10.1182/asheducation-2015.1.507

Published: 2015

NARROW

Opportunities for immunotherapy in childhood acute myeloid leukemia

Minimal residual disease and stem cell transplantation outcomes

Single-agent and combination biologics in acute myeloid leukemia

In MDS, is higher risk higher reward?

MRD evaluation of AML in clinical practice: are we there yet?

Evidence-Based Minireview: Longitudinal geriatric assessment in quality care for older patients with hematologic malignancies

Genetic predisposition to MDS: diagnosis and management

Moving immunotherapy into the front line in ALL

Monitoring and treatment of MDS in genetically susceptible persons

The MDS genomics-prognosis symbiosis

When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter

Cytotoxic therapy in acute myeloid leukemia: not quite dead yet

New drugs for acute myeloid leukemia inspired by genomics and when to use them

Old and new tools in the clinical diagnosis of inherited bone marrow failure syndromes

Inherited bone marrow failure syndromes: considerations pre- and posttransplant

Classification and risk assessment in AML: integrating cytogenetics and molecular profiling

The role of targeted therapy in the management of patients with AML

Fitness in the elderly: how to make decisions regarding acute myeloid leukemia induction

MRD in AML: does it already guide therapy decision-making?

Acute myeloid leukemia in children and adolescents: identification of new molecular targets brings promise of new therapies

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only